MEDP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Medpace Holdings Inc (MEDP) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available. Despite strong financial performance in Q4 2025, the stock is currently oversold with negative technical indicators, mixed analyst sentiment, and a lack of strong proprietary trading signals. The investor should consider waiting for clearer positive momentum or a more favorable entry point.
The stock is currently oversold with an RSI of 4.191, indicating extreme bearish momentum. The MACD histogram is -19.955 and negatively expanding, signaling continued downward pressure. Moving averages are converging, and the stock is trading near its S1 support level of 424.91. The pre-market price of 424.8 reflects a slight recovery (+2.11%) but does not confirm a reversal.
Strong Q4 2025 financial results with revenue up 32.03% YoY and EPS up 26.98% YoY.
Analysts like Baird see Medpace as a long-term beneficiary of AI-driven growth in the biopharma sector.
Pre-market price shows a slight recovery (+2.11%).
Elevated backlog cancellations in obesity and metabolic programs, leading to a disappointing book-to-bill ratio.
Analysts have lowered price targets significantly, reflecting concerns about AI CRO disintermediation and cancellations.
Gross margin dropped by -12.13% YoY in Q4 2025, indicating potential cost pressures.
Hedge funds and insiders show neutral sentiment with no significant trading activity.
Medpace reported strong Q4 2025 results with revenue of $708.5 million (+32.03% YoY), net income of $135.13 million (+15.48% YoY), and EPS of $4.66 (+26.98% YoY). However, gross margin declined to 27.97%, down -12.13% YoY, which could signal rising costs or pricing pressures.
Analyst sentiment is mixed. Baird upgraded the stock to Outperform, citing long-term AI benefits, but lowered the price target to $564 from $658. Mizuho and Truist also lowered price targets while maintaining positive ratings. BMO Capital and Barclays remain cautious, citing ongoing cancellations and AI CRO disintermediation concerns.
